Key Takeaways TBLA increased R&D spending to 8% of revenues in 2024 to drive AI-led product innovation and ad performance. Sustained R&D enables TBLA to improve contextual targeting, ad relevance and user engagement. Investments in generative AI and self-serve tools help TBLA expand offerings and enter new ad tech markets.Taboola.com Ltd. (TBLA) places strong emphasis on research and development (R&D) as a fundamental pillar of its long-term growth and competitiveness. In an ever-evolving digital advertis ...

CoreWeave is acquiring data center infrastructure provider Core Scientific in a $9 billion deal.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.The artificial intelligence (AI) company announced the deal Monday (Ju ...

Group 1 - CoreWeave signed a $9 billion all-stock deal to acquire Core Scientific, a data center infrastructure provider [1] - The acquisition will provide CoreWeave with over 1 gigawatt of data center capacity, sufficient to power more than 850,000 homes, for AI training and inference workloads [1] - Core Scientific, previously focused on Bitcoin mining, will now utilize its GPUs for running and training generative AI models [1] Group 2 - Cloud infrastructure providers are expanding their data center capacity to meet the growing computational demands of AI companies [2] - OpenAI has entered into a deal to rent an additional 4.5 gigawatts of data center capacity from Oracle, enhancing their existing Stargate infrastructure agreement [2]

Core Insights - Pegasystems (PEGA) is experiencing accelerated growth in its cloud segment, with Pega Cloud's Annual Contract Value (ACV) increasing by 23% year-over-year to $701 million in Q1 2025, driven by demand for AI-powered, cloud-native solutions [1][3] - The company's cloud revenues rose 15% year-over-year to $151.1 million, highlighting the strength of its recurring revenue model [1][9] - Pegasystems aims to grow Cloud ACV by 20% or more, supported by successful cross-selling, upselling, and new client acquisitions [3][9] Cloud Momentum - There is a clear shift among enterprises towards scalable and intelligent automation, with PEGA's AI-infused platforms simplifying digital transformation and enhancing client retention [2] - The increase in ACV indicates deeper customer engagement and more durable multi-year contracts as workloads transition from legacy systems to the cloud [2] Competitive Landscape - Salesforce (CRM) is a strong competitor in cloud-native CRM and low-code workflows, leveraging its extensive integrations and partnerships to enhance its market position [5] - Oracle (ORCL) competes with PEGA in process automation, excelling in infrastructure and large-scale deployments, while PEGA stands out in BPM usability and AI-driven decision-making [6] Stock Performance and Valuation - Pegasystems shares have gained 16% year-to-date, outperforming the broader Zacks Computer and Technology sector, which returned 8.2%, and the Computer-Software industry, which rose 17% [7][9] - The Zacks Consensus Estimate for PEGA's earnings is $1.88 per share for 2025, reflecting a year-over-year growth of 24.5% [11]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Group 1 - The article highlights an increasing focus on UK-based companies, particularly in sectors such as energy, telecommunications, finance, and consumer staples [1] - The author has been actively investing more capital into these UK-based companies, indicating a positive outlook on their performance [1] Group 2 - There is a mention of a beneficial long position in the shares of SEMHF, suggesting confidence in the stock's future performance [1]

Core Viewpoint - Essex Property Trust (ESS) has experienced a stock price increase of 12.6% over the past three months, outperforming the industry average of 8.6% [1][9] Group 1: Company Performance and Market Position - The company is well-positioned to benefit from a strong West Coast property base, supported by various demand drivers such as job creation and income growth from technology companies [4] - The slowing layoffs in the tech industry and the return to office trends are expected to boost renter demand in West Coast markets, leading to healthy demand and revenue growth for ESS [4] - The company has made significant efforts to enhance its operational efficiency through technology and scale, which is anticipated to drive margin expansion and contribute to both top-line and bottom-line growth [5] Group 2: Financial Health - As of March 31, 2025, Essex Property maintains a robust balance sheet with $1.4 billion in liquidity, derived from undrawn credit facilities, cash, and marketable securities [6][9] - The company has achieved a 92% adjusted total net operating income (NOI) and holds investment-grade ratings of Baa1/Stable and BBB+/Stable from Moody's and S&P, respectively [7] Group 3: Dividend Growth - Essex Property has consistently increased its dividend payouts, raising them five times in the last five years, with a five-year annualized growth rate of 4.95%, indicating a sustainable dividend payout in the long run [10]

Core Viewpoint - Jasper Therapeutics, Inc. is facing a significant decline in stock price, dropping nearly 55% amid high trading volume, following the release of updated data from its BEACON study on briquilimab for chronic spontaneous urticaria (CSU) [1][10]. Group 1: Study Results - The BEACON Phase 1b/2a study reported briquilimab's safety, tolerability, and clinical activity, with primary endpoints focusing on these aspects [2]. - In the study, 89% of participants achieved a complete response, and 78% achieved a clinical response by week 2 [4]. - Mean changes in Urticaria Activity Score over 7 days (UAS7) showed reductions of 28.3 points in the 240mg cohort and 22.9 points in the 360mg cohort at 4 weeks [4]. Group 2: Ongoing Investigations and Adjustments - The company is investigating issues related to a specific drug product lot that affected results in certain cohorts, with findings expected in the coming weeks [6]. - Additional patient enrollment is planned to strengthen the data set for the Phase 2b CSU study, with results anticipated in Q4 2025 and study commencement expected in mid-2026 [7]. Group 3: Strategic Changes - To prioritize resources for briquilimab in CSU, the company is halting the asthma study and pausing development in severe combined immunodeficiency (SCID) [8]. - Cost-cutting measures, including potential restructuring, are being implemented to extend the company's financial runway [8].

Core Transaction Overview - Core Scientific is involved in a transaction with CoreWeave, where shareholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific, valuing the deal at approximately $9.0 billion [2]. Investigation Details - The Ademi Firm is investigating Core Scientific for potential breaches of fiduciary duty and other legal violations related to the transaction with CoreWeave [1]. - The investigation focuses on whether the Core Scientific board of directors is fulfilling their fiduciary duties to all shareholders, particularly in light of the transaction's terms [3]. Transaction Restrictions - The transaction agreement imposes significant penalties on Core Scientific if it accepts competing bids, which may unreasonably limit other potential transactions [3].

Core Viewpoint - Wolfspeed's stock has experienced significant gains, rising 96.6% despite broader market declines, following the announcement of a new CFO, Gregor van Issum [1][3]. Group 1: Stock Performance - Wolfspeed's share price increased by as much as 122.2% before 1 p.m. ET on the announcement of the new CFO [1]. - The stock had previously suffered a decline in May due to bankruptcy filing reports, but has since rebounded substantially [3]. Group 2: Leadership Change - Gregor van Issum will take over as CFO on September 1, succeeding interim CFO Kevin Speirits [3]. - Van Issum brings over two decades of experience in corporate restructuring and strategic financing, which investors hope will aid in the company's financial transition [4]. Group 3: Financial Outlook - Wolfspeed is currently undergoing bankruptcy and financial restructuring proceedings, which raises concerns about the high level of debt and potential dilution of current shareholders' equity [3][4]. - While there is potential for significant stock price increases, there is also a high risk of substantial losses for investors [4].